A Randomized, Blinded, Placebo-Controlled Study To Evaluate The Effect Fixed-Dose Leucine, Metformin, Sildenafil Combinations(NS-0200) Versus Placebo On Hepatic Fat Assessed By MRI In Non Alcoholic Fatty Liver Disease Patients
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Leucine/metformin/sildenafil (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- Acronyms TRIPLN
- Sponsors NuSirt Biopharma
- 07 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Planned End Date changed from 1 Feb 2017 to 1 May 2017.
- 13 Jan 2017 Planned End Date changed from 1 Jan 2017 to 1 Feb 2017.